Bristol-Myers Squibb shares fall on $74 billion Celgene acquisition

Business


Georges Gobet | AFP | Getty Images

Tablets are pictured on the production line of Bristol Myers Squibb’s pharmaceutical plant of French group UPSA.

Bristol-Myers Squibb is making a $74 billion bet — and investors aren’t pleased.

The New York-based pharmaceutical giant on Thursday said it would acquire Celgene, a Summit, New Jersey-based cancer drug company, in a cash and stock deal valued at $74 billion. Under the agreement, Celgene shareholders will receive one Bristol-Myers Squibb share and $50 in cash for each Celgene share held, or $102.43 per share, a premium of 53.7 percent to Celgene’s Wednesday close.

After factoring in debt, the value of the deal balloons to about $95 billion — making it the largest health-care deal on record, according to data compiled by Refinitiv.

Celgene investors were jubilant over the deal while Bristol investors were less than enthused. Shares of Bristol slid 12 percent while shares of Celgene surged 25 percent shortly after it was announced. There’s a chance Bristol investors, who think the company is overpaying for Celgene, may not approve the acquisition, Mizuho Securities USA said after conducting a quick survey of about 100 institutional clients.



Source link

Products You May Like

Articles You May Like

CSX shares fall after the railroad operator forecast less robust revenue growth for 2019
One unique method of picking stocks is outperforming in 2019
Three things your child should know before taking on student loans
Trading on Wall Street is struggling and could mean bad news
Disney’s streaming efforts are already losing more than $1 billion

Leave a Reply

Your email address will not be published. Required fields are marked *